Drug survival of Adalimumab and Infliximab in Hidradenitis Suppurativa Patients: A Daily Practice Cohort Study.

CONCLUSION: Survival rates are comparable for adalimumab and infliximab at 12 months and are mainly determined by ineffectiveness. Age, disease duration (adalimumab) and surgery (infliximab) are predictors for longer survival.
PMID: 33544917 [PubMed - as supplied by publisher]

Source: The British Journal of Dermatology - February 5, 2021 Category: Dermatology Authors: Prens LM, Bouwman K, Aarts P, Arends S, van Straalen KR, Dudink K, Horváth B, Prens EP Tags: Br J Dermatol Source Type: research